Rezolute Inc RZLT

$4.87 +0.23 (4.96%)

Valuation

Market cap
471,070,000
Revenue TTM
$0
Net income TTM
$-77,590,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,873,600
Avg volume
1,551,518
Day's range
$4.55 – $4.91
Shares out
96,729,000
Stochastic %K
96%
Beta
0.53
Analysts
Strong Sell
Price target
$9.80

Price

Company profile

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly kn...

Show more

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 206 4507
Website
https://www.rezolutebio.com
Address
275 Shoreline Drive, Suite 500, Redwood City, United States

Latest news

Stocktwits

Merlintrader Oct 11, 9:28 AM
Hyperinsulinism: $RZLT $AMLX ZEAL(CPH) 128940(KOSPI) Rezolute, Amylyx, Zealand and Hanmi are not interchangeable hyperinsulinism trades. The comparison separates tumor and congenital disease, trial endpoints, regulatory uncertainty and financing. ZEAL is Copenhagen-listed; Hanmi 128940 is Korea-listed, not a US ticker. Full comparative research: https://www.merlintrader.com/rzlt-amlx-zealand-hanmi-hyperinsulinism-catalyst-comparison/
0 replies
Merlintrader Oct 10, 10:23 PM
$RZLT: upLIFT topline is expected in Q4 2026. FDA encouraged a congenital-HI pre-BLA meeting but gave no approvability opinion. Our hub separates the two indications, evidence and funding risks. https://www.merlintrader.com/rezolute-stock-hub/
0 replies
Monty3030 Oct 9, 5:45 PM
$RZLT Interested to see what next week brings with the option chain expiring..
1 replies
oaksapollo Oct 9, 1:48 PM
$RZLT Any thoughts on when upLIFT reads out? Treatment duration is 8 weeks and right now clinicaltrials.gov still shows it as recruiting. That seems to create an extremely narrow window between mid-December and end of 2026 for top line data. Not really an ideal time to be announcing top line results with many people out for the holidays. However they seem so confident that the study will read out this quarter. Maybe they are over-enrolling the study, and they've already hit the 16 needed to trigger primary analysis?
1 replies
KONGLIVES1 Oct 8, 3:48 PM
$RZLT the only thing scaring me today is the volume, but it’s one of the few that is up today 
0 replies
Hurricane76 Oct 7, 2:51 PM
$RZLT i thino thos one hits 5+ in the next few days if the market cooperates
0 replies
oaksapollo Oct 7, 2:10 PM
$RZLT Can anyone think of a reason why Rezolute would not get acquired at this point? cHI is back on the table, we know tumor HI is pretty much a slam dunk. Why wait any longer? This whole company is 1 molecule so it would be so easy for any company working in the rare disease space to add it to their pipeline. No complex integrations, no phase 1 or phase 2 assets to sort out. Nobody wants to see RZLT file a BLA. Let's leave that to the professionals who do it day in and day out.
1 replies
VolumeSpreadAnalysis Oct 7, 3:13 AM
$RZLT Price: $4.32 Volume: Above average Catalyst: Traders are reacting to updates on RZLT’s pipeline progress and potential partnership/data readouts. Resistance: $4.75 Support: $3.90 Bull case: A move through $4.75 on strong volume could spark a breakout toward $5.50. Bear case: Failure to hold $3.90 support may send shares back toward $3.50. What I'm watching: Watching for sustained volume above average and a clean close above resistance to confirm strength. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services.
0 replies